CRH Medical logo Media stories about CRH Medical (CVE:CRM) have trended very positive recently, InfoTrie reports. The research firm ranks the sentiment of news coverage by analyzing more than 6,000 news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. CRH Medical earned a news impact score of 3.14 on their scale. InfoTrie also gave media stories about the company an news buzz score of 5 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company’s share price in the near term.
CRH Medical has a 12-month low of C$83.00 and a 12-month high of C$128.87.
CRH Medical Company Profile
CRH Medical Corporation (CRH) specializes in the distribution of medical products directly to physicians, particularly those in the gastroenterologist community. The Company’s lead product, the CRH O’Regan System, is a single use, disposable, hemorrhoid treatment that is used in treating hemorrhoid grades I-IV.
Read More: Do back-end load funds outperform no-load funds?
Receive News & Ratings for CRH Medical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CRH Medical and related companies with MarketBeat.com’s FREE daily email newsletter .
Click here to view original web page at Very Favorable News Coverage Somewhat Likely to Affect CRH Medical (CRM) Stock Price